Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 284

1.

Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.

Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, Hampel H, Borgen P, Brown K, Skolnick M, Shattuck-Eidens D, Jhanwar S, Goldgar D, Offit K.

Nat Genet. 1996 May;13(1):126-8.

PMID:
8673092
2.

The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.

Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K.

Nat Genet. 1996 Oct;14(2):188-90.

PMID:
8841192
3.

The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.

Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T.

Am J Hum Genet. 1997 Mar;60(3):505-14.

4.

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.

Roa BB, Boyd AA, Volcik K, Richards CS.

Nat Genet. 1996 Oct;14(2):185-7.

PMID:
8841191
5.

A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.

Berman DB, Costalas J, Schultz DC, Grana G, Daly M, Godwin AK.

Cancer Res. 1996 Aug 1;56(15):3409-14.

6.

Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.

Lehrer S, Fodor F, Stock RG, Stone NN, Eng C, Song HK, McGovern M.

Br J Cancer. 1998 Sep;78(6):771-3.

7.

Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.

Shiri-Sverdlov R, Oefner P, Green L, Baruch RG, Wagner T, Kruglikova A, Haitchick S, Hofstra RM, Papa MZ, Mulder I, Rizel S, Bar Sade RB, Dagan E, Abdeen Z, Goldman B, Friedman E.

Hum Mutat. 2000 Dec;16(6):491-501.

PMID:
11102978
8.

A family with three germline mutations in BRCA1 and BRCA2.

Liede A, Metcalfe K, Offit K, Brown K, Miller S, Narod SA, Moslehi R.

Clin Genet. 1998 Sep;54(3):215-8.

PMID:
9788724
10.

An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews.

Lalloo F, Cochrane S, Bulman B, Varley J, Elles R, Howell A, Evans DG.

J Med Genet. 1998 Jan;35(1):10-2.

11.

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.

Clin Cancer Res. 2002 Dec;8(12):3776-81.

12.

Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer.

Gershoni-Baruch R, Dagan E, Fried G, Bruchim Bar-Sade R, Sverdlov-Shiri R, Zelicksson G, Friedman E.

Eur J Cancer. 2000 May;36(8):983-6.

PMID:
10885601
13.

The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.

Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA.

Am J Hum Genet. 1999 Apr;64(4):963-70.

14.

Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women.

Distelman-Menachem T, Shapira T, Laitman Y, Kaufman B, Barak F, Tavtigian S, Friedman E.

Fam Cancer. 2009;8(2):127-33. doi: 10.1007/s10689-008-9216-6. Epub 2008 Sep 17.

PMID:
18798010
15.

Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.

Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet JS, Narod S.

J Natl Cancer Inst. 1999 Jul 21;91(14):1241-7.

PMID:
10413426
16.

A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.

Phelan CM, Kwan E, Jack E, Li S, Morgan C, Aubé J, Hanna D, Narod SA.

Hum Mutat. 2002 Nov;20(5):352-7.

PMID:
12402332
17.

High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history.

Beller U, Halle D, Catane R, Kaufman B, Hornreich G, Levy-Lahad E.

Gynecol Oncol. 1997 Nov;67(2):123-6.

PMID:
9367693
18.

Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer.

Krainer M, Silva-Arrieta S, FitzGerald MG, Shimada A, Ishioka C, Kanamaru R, MacDonald DJ, Unsal H, Finkelstein DM, Bowcock A, Isselbacher KJ, Haber DA.

N Engl J Med. 1997 May 15;336(20):1416-21.

19.

Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls.

Muto MG, Cramer DW, Tangir J, Berkowitz R, Mok S.

Cancer Res. 1996 Mar 15;56(6):1250-2.

20.

Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.

Karp SE, Tonin PN, Bégin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD.

Cancer. 1997 Aug 1;80(3):435-41.

PMID:
9241077

Supplemental Content

Support Center